Adaptimmune Therapeutics Sees Unusually Large Options Volume (ADAP)

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) was the target of unusually large options trading activity on Thursday. Stock investors purchased 508 call options on the stock. This is an increase of approximately 896% compared to the typical daily volume of 51 call options.

Shares of ADAP stock opened at $11.50 on Friday. The stock has a market cap of $1,068.03, a PE ratio of -13.86 and a beta of 1.79. Adaptimmune Therapeutics has a 1 year low of $4.15 and a 1 year high of $13.41.

How to Become a New Pot Stock Millionaire

ADAP has been the topic of several research reports. ValuEngine cut shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub raised shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday. Leerink Swann reissued an “outperform” rating on shares of Adaptimmune Therapeutics in a research report on Thursday, March 15th. Finally, Zacks Investment Research cut shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 19th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $11.58.

In other news, CFO Adrian Rawcliffe sold 600,000 shares of the stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $1.71, for a total transaction of $1,026,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David M. Mott purchased 869,574 shares of Adaptimmune Therapeutics stock in a transaction dated Thursday, March 22nd. The shares were acquired at an average cost of $1.90 per share, for a total transaction of $1,652,190.60. The disclosure for this purchase can be found here. Insiders have bought 2,242,926 shares of company stock worth $4,264,809 in the last three months. Corporate insiders own 24.45% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. Vident Investment Advisory LLC increased its stake in shares of Adaptimmune Therapeutics by 3.1% during the third quarter. Vident Investment Advisory LLC now owns 251,145 shares of the biotechnology company’s stock worth $2,057,000 after buying an additional 7,610 shares during the period. OxFORD Asset Management LLP increased its stake in shares of Adaptimmune Therapeutics by 30.1% during the third quarter. OxFORD Asset Management LLP now owns 45,238 shares of the biotechnology company’s stock worth $369,000 after buying an additional 10,471 shares during the period. Alps Advisors Inc. increased its stake in shares of Adaptimmune Therapeutics by 12.7% during the fourth quarter. Alps Advisors Inc. now owns 103,816 shares of the biotechnology company’s stock worth $693,000 after buying an additional 11,716 shares during the period. Essex Investment Management Co. LLC increased its stake in shares of Adaptimmune Therapeutics by 19.6% during the fourth quarter. Essex Investment Management Co. LLC now owns 87,307 shares of the biotechnology company’s stock worth $583,000 after buying an additional 14,311 shares during the period. Finally, Raymond James & Associates purchased a new stake in shares of Adaptimmune Therapeutics during the fourth quarter worth approximately $114,000. Hedge funds and other institutional investors own 55.58% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Adaptimmune Therapeutics Sees Unusually Large Options Volume (ADAP)” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3294483/adaptimmune-therapeutics-sees-unusually-large-options-volume-adap.html.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

First Internet Bancorp’s  Buy Rating Reiterated at Maxim Group
First Internet Bancorp’s Buy Rating Reiterated at Maxim Group
Show  Reaches Market Cap of $0.00
Show Reaches Market Cap of $0.00
PayCoin  Price Tops $0.0344 on Major Exchanges
PayCoin Price Tops $0.0344 on Major Exchanges
UGAIN Price Reaches $0.0031
UGAIN Price Reaches $0.0031
Reviewing Sally Beauty  and Kirkland’s Home
Reviewing Sally Beauty and Kirkland’s Home
Comparing CGG  and Paramount Resources
Comparing CGG and Paramount Resources


© 2006-2018 Ticker Report. Google+.